U.S. Stem Cell, Inc.
Other OTCTotal Valuation
U.S. Stem Cell, Inc. carries a market capitalization of 64,151.00, placing it among publicly traded companies globally. Its enterprise value stands at 11.71M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 64,151.00 |
| Enterprise Value | 11.71M |
Share Statistics
U.S. Stem Cell, Inc. currently has 634.40M shares outstanding.
| Shares Outstanding | 634.40M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 33.74, and the price-to-book ratio stands at -0.02.
| PE Ratio | N/A |
| PS Ratio | 33.74 |
| PB Ratio | -0.02 |
| P/TBV Ratio | -0.19 |
| P/FCF Ratio | -9.08 |
| P/OCF Ratio | -9.08 |
Enterprise Valuation
| EV / Sales | 142.72 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | 30.41 |
Financial Position
U.S. Stem Cell, Inc. maintains a current ratio of 0.00, meaning it holds 0.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -60.68, indicating conservative leverage, while an interest coverage ratio of -2.49 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.00 |
| Quick Ratio | 0.00 |
| Debt / Equity | -60.68 |
| Debt / EBITDA | -5.20 |
| Interest Coverage | -2.49 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -4,801.73 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 34.62 |
Income Statement
Over the trailing twelve months, U.S. Stem Cell, Inc. generated 82,049.00 in revenue and converted that into -2.86M in net income, yielding earnings per share of 0.00. EBITDA reached -1.72M, while operating income came in at -1.72M.
| Revenue | 82,049.00 |
| Gross Profit | 58,282.00 |
| Operating Income | -1.72M |
| Pretax Income | -2.86M |
| Net Income | -2.86M |
| EBITDA | -1.72M |
| EBIT | -1.72M |
| Earnings Per Share (EPS) | 0.00 |
Balance Sheet
U.S. Stem Cell, Inc. holds 5,133.00 in cash and equivalents against 8.95M in total debt, resulting in a net debt position of 8.94M. Total book value stands at -141.88M, with working capital of -14.01M providing operational flexibility.
| Cash & Cash Equivalents | 5,133.00 |
| Total Debt | 8.95M |
| Net Debt | 8.94M |
| Equity (Book Value) | -141.88M |
| Book Value Per Share | -0.25 |
| Working Capital | -14.01M |
Cash Flow
U.S. Stem Cell, Inc. produced -304,852.00 in operating cash flow over the past twelve months.
| Operating Cash Flow | -304,852.00 |
| Capital Expenditures | N/A |
| Free Cash Flow | -304,852.00 |
| FCF Per Share | 0.00 |
Margins
U.S. Stem Cell, Inc. operates with a gross margin of 71.03, reflecting its pricing power and cost economics. The operating margin of -2,096.90 and net profit margin of -3,483.21 provide insight into operational efficiency.
| Gross Margin | 71.03 |
| Operating Margin | -2,096.90 |
| Pretax Margin | -3,483.21 |
| Profit Margin | -3,483.21 |
| EBITDA Margin | -2,096.90 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -9.77 |
| FCF Yield | -11.01 |
Stock Splits
U.S. Stem Cell, Inc.'s most recent stock split took place on November 4, 2015 with a 1000:1 split ratio.
| Last Split Date | 11/4/2015 |
| Split Ratio | 1000:1 |
Scores
U.S. Stem Cell, Inc. posts an Altman Z-Score of -3,261.72, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -3,261.72 |